The report “Investigation Report on China Olmesartan Market, 2009-2018″ by China Research and Intelligence is now available at chinamarketresearchreports.com. Contact firstname.lastname@example.org with Research Report on Investigation Report on China Olmesartan Market, 2009-2018 in subject line and your contact details to purchase this report or get your questions answered.
The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Olmesartan Market, 2009-2018”On chinamarketresearchreports.com . According to statistics from WHO, onethird of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack. Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Developed by Sankyo and Forest Laboratories, olmesartan medoxomil was approved to the U.S.A. in April 2002 with the trade name "Benicar" and was approved to Europe in October 2002. In July 2006, it was launched in Chinese market. Olmesartan can take effect very soon with low dosage, and it has strong and lasting antihypertensive effect with few adverse reactions, especially dry cough. Also because of its excellent performance worldwide, many Chinese manufacturers applied to produce the generic drug. However, this behavior caused the noted "composition patent" olmesartan patent infringement case in 2006, resulting in the "Bolar Exception" in Chinese patent system. Although Beijing Winsunny Pharmaceutical Co., Ltd. won the trial and was approved to produce the genetic drug in 2007, they violates Sankyo's patent every time they produce or sell the product. For Beijing Winsunny Pharmaceutical Co., Ltd., it has won the trial but not the market. Competition pattern of olmesartan medoxomil manufacturers from Menet indicates that olmesartan medoxomil produced by Beijing Winsunny Pharmaceutical Co., Ltd. could not go on the market...
Please join StudyMode to read the full document